Under the Paperwork Reduction Act of 1986, no persons are required to respond to a collection of information unless storates a valid CMB control number

Application Number 09576063

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

	Application Number		09576063
	Filing Date		2000-05-22
	First Named Inventor	Darsu	ke Terasawa
	Art Unit		2617
	Examiner Name	Inder	P. Mehra
	Attorney Docket Number		000307

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	late	Name of Pate of cited Docu	entee or Applicant ment	Relev	s,Columns,Lines where rant Passages or Relev es Appear	
	1	6363060		2002-03	-26	Sandip Sarkar				
If you wish to add additional U.S. Patent citation information please click the Add button.									_	
U.S.PATENT APPLICATION PUBLICATIONS										
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wish	h to ac	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	please click the Ad	d butto	n.	
				FOREIG	SN PAT	TENT DOCUM	ENTS			
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	ent Country Code <sup>2</sup> i		Kind Code <sup>4</sup>	Publication Date	Applicant of cited		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS.
	1	WO 98/44669	wo			1998-10-08	Motorola Inc.			
If you wish to add additional Foreign Patent Document citation information please click the Add button										

NON-PATENT LITERATURE DOCUMENTS
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

publisher, city and/or country where published.

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

**T**5

U.S.PATENTS

Initials\* No

Examiner Cite

#### Application Number 09576063 Filing Date 2000-05-22 INFORMATION DISCLOSURE First Named Inventor Daisuke Terasawa STATEMENT BY APPLICANT Art Unit 2617 ( Not for submission under 37 CFR 1.99) Examiner Name Inder P. Mehra

	1	European Search Report, Mailed 2006-11-28, Application No. 06022087.8 - 2411, pp. 1-3.					
	2	3GPP, "Universal Mobile Telecommunications System (UMTS)", ETIS Standards, European Telecommunications Standards Institute, Sophia-Antipo, FR, vol. 3-RZ, no. V320, March 2000 (2000-03), pages 1-507, XP 014008794.					
If you wish to add additional non-patent literature document citation information please click the Add button							

Attorney Docket Number

000307

**EXAMINER SIGNATURE** Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 4 Applicant is to place a check mark here if English language translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

	Application Number		09576063		
	Filing Date		2000-05-22		
	First Named Inventor	Daisu	Daisuke Terasawa		
	Art Unit		2617		
	Examiner Name	Inder	er P. Mehra		
	Attornou Docket Number		000307		

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c).

- See attached certification statement
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Won Tae Kim

√ Non

Name/Print

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature

Registration Number

40457

Signature	/Won Tae Kim/	Date (YYYY-MM-DD)	2007-02-16

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is gowered by \$5 U.S. C. 12.9 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P. 0. 80x 1453, (Alexandri, V.S.2313-1450, D. ON TO SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, VA.22313-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given centain information in connection with your submission of the attached from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2(b)(2); (2) furnishing of the information solicided to is coluntary, and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan (Affice is to process and/or administ purpus submission related to a patient agricultant or patient. If you do not furnish the requested process and/or administration of the patient and the process and the p

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. S52(am).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a noutine use, to the Administrator, General Services, or hisher designer, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the conditions.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 152(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitation of 37 CFR 1.14, as a routine use, to the public if the record was filled in application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.